Q4 2025 GVS SpA Earnings Call Transcript
Key Points
- GVS SpA (STU:4YQ) reported a 2% increase in sales, excluding FX, reaching EUR 425 million compared to 2024.
- The adjusted EBITDA increased by 3% to EUR 107 million, with a margin improvement from 24.3% to 25.2%.
- The Safety division showed strong performance with nearly 12% growth, excluding FX.
- The Transfusion Medicine segment recorded a significant growth of approximately 30%, driven by M&A contributions.
- The company successfully reduced its leverage ratio from 2.1x to 1.6x, excluding external effects, indicating improved financial stability.
- The Energy Mobility division experienced a decline in sales by 7.5%, excluding FX.
- The US Dialysis business negatively impacted volumes, contributing to a EUR 10 million decrease.
- The Life Sciences division reported a negative performance of 3.7%, despite improvements in the fourth quarter.
- The company faces a negative FX impact of EUR 12.5 million, primarily due to the depreciation of the US dollar.
- GVS SpA anticipates challenges in the MedTech division due to the ongoing decline in the dialysis business.
Good afternoon. This is the conference operator. Welcome, and thank you for joining the GVS full-year 2025 results web call. (Operator Instructions) At this time, I would like to turn the conference over to Mr. Massimo Scagliarini, CEO of GVS. Please go ahead, sir.
Thank you. Good afternoon, and good morning to everybody. Welcome to the 2025 results presentation of the GVS Group. A quick snapshot on the number.
So yes, I hope everyone can see. So sales at EUR425 million, plus 2%, excluding FX versus 2024. Adjusted EBITDA EUR107 million, so plus 3% versus 2024 and 25.2% as a margin, 95 bps better than previous year. Adjusted net income, net of FX impact at plus 5.9%, EUR47.4 million, increasing the margin to 11.2% from the 10.4% of 2024. Net financial position, EUR240 million with a leverage ratio post M&A at 2.2x.
So these are the quick snapshot. Now some more detail by division. So we have the Healthcare and Life Sciences division at plus 1.5% versus previous year
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
